血清 CYR61 作为诊断食管胃结合部肿瘤的潜在生物标志物。
Serum CYR61 as a potential biomarker for the diagnosis of esophagogastric junction tumor.
机构信息
Department of Clinical Laboratory Medicine, the Cancer Hospital of Shantou University Medical College, Shantou, China.
Department of Biochemistry and Molecular Biology, Shantou University Medical College, Shantou, China.
出版信息
Biosci Rep. 2021 Jun 25;41(6). doi: 10.1042/BSR20204117.
BACKGROUND
Esophagogastric junction tumor (EGJ) is a rare but fatal disease with a rapid rising incidence worldwide in the late 20 years, and it lacks a convenient and safe method for diagnosis. The present study aimed to evaluate the potential of serum CYR61 as a biomarker for the diagnosis of EGJ tumor.
METHODS
Enzyme-linked immunosorbent assay (ELISA) was used to estimate CYR61 levels in sera of 152 EGJ tumor patients and 137 normal controls. Receiver operating characteristics (ROC) was carried out to evaluate the diagnostic accuracy. The Mann-Whitney's U test was used to compare the difference of serum levels of CYR61 between groups. And chi-square tests were employed to estimate the correlation of the positive rate of serum CYR61 between/among subgroups.
RESULTS
Serum CYR61 levels were statistically lower in EGJ tumor and early-stage EGJ tumor patients than those in normal controls (P<0.0001). The sensitivity, specificity and the area under the curve (AUC) of this biomarker in EGJ tumor were 88.2%, 43.8% and 0.691, respectively, and those for early stage of EGJ tumor were 80.0%, 66.4% and 0.722, respectively. Analyses showed that there was no correlation between the clinical data and the levels of CYR61 (P>0.05).
CONCLUSION
The present study showed that CYR61 might be a potential biomarker to assist the diagnosis of EGJ tumor.
背景
食管胃结合部肿瘤（EGJ）是一种罕见但致命的疾病，在过去 20 年中，全球发病率迅速上升，目前缺乏一种方便、安全的诊断方法。本研究旨在评估血清 CYR61 作为 EGJ 肿瘤诊断标志物的潜力。
方法
采用酶联免疫吸附试验（ELISA）检测 152 例 EGJ 肿瘤患者和 137 例正常对照者血清 CYR61 水平。采用受试者工作特征（ROC）曲线评价诊断准确性。采用 Mann-Whitney U 检验比较各组血清 CYR61 水平的差异。采用卡方检验估计血清 CYR61 阳性率在亚组间/内的相关性。
结果
EGJ 肿瘤和早期 EGJ 肿瘤患者血清 CYR61 水平明显低于正常对照组（P<0.0001）。该标志物对 EGJ 肿瘤的敏感性、特异性和曲线下面积（AUC）分别为 88.2%、43.8%和 0.691，对早期 EGJ 肿瘤的敏感性、特异性和 AUC 分别为 80.0%、66.4%和 0.722。分析表明，CYR61 水平与临床资料无相关性（P>0.05）。
结论
本研究表明，CYR61 可能是一种辅助诊断 EGJ 肿瘤的潜在标志物。
Zotero 插件